About: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Creator	Wang, Wei Hu, Yi Chen, Wei Wang, Lei Jiang, Tao Zhu, Feng-Cai Wang, Zhao Wang, Ling Wang, Wen-Juan Gou, Jin-Bo Guan, Xu-Hua Hou, Li-Hua Jia, Si-Yue Jiang, Hu-Dachuan Li, Jing-Xin Li, Yu-Hua Wang, Bu-Sen Wang, Xue-Wen Wu, Shi-Po Xu, Jun-Jie Xu, Sha-Bei
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. METHODS: We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 10(10), 1 × 10(11), and 1·5 × 10(11) viral particles) to receive an intramuscular injection of vaccine. The primary outcome was adverse events in the 7 days post-vaccination. Safety was assessed over 28 days post-vaccination. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. This study is registered with ClinicalTrials.gov, NCT04313127. FINDINGS: Between March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination. INTERPRETATION: The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation. FUNDING: National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1016/s0140-6736(20)31208-3
bibo:pmid	32450106
has license	no-cc
sha1sum (hex)	4b5b4f469bec44d37f2778a873c902f480eaa6ea
schema:url	https://doi.org/10.1016/s0140-6736%2820%2931208-3
resource representing a document's title	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
has PubMed Central identifier	PMC7255193
has PubMed identifier	32450106
schema:publication	Lancet
resource representing a document's body	covid:4b5b4f469bec44d37f2778a873c902f480eaa6ea#body_text
is schema:about of	named entity 'adenovirus' named entity 'recombinant' named entity 'TOLERABILITY' named entity 'immunogenicity' named entity 'COVID-19' named entity 'tolerability' named entity 'recombinant' named entity 'adenovirus' named entity 'COVID-19 vaccine' named entity 'immunogenicity' named entity 'vaccine' named entity 'tolerability' named entity 'recombinant' named entity 'glycoprotein' named entity 'principal investigator' named entity 'immune responses' named entity 'infection' named entity 'CD8 +' named entity 'SARS-CoV-2' named entity 'vaccination' named entity 'sputum' named entity 'neutralising antibody' named entity 'RBD' named entity 'adverse events' named entity 'fever' named entity 'antibody-dependent enhancement' named entity 'vaccination' named entity 'CanSino Biologics' named entity 'adverse reactions' named entity 'vaccination' named entity 'correlates of protection' named entity '28 days' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'seroconversion' named entity 'vaccination' named entity 'primary endpoint' named entity 'Ad5' named entity 'cardiovascular conditions' named entity 'vaccination' named entity 'Multivariable analysis' named entity 'adverse reactions' named entity 'viral particles' named entity 'IFNγ' named entity 'seroconversion' named entity 'vaccination' named entity 'CD4' named entity 'China' named entity 'antibodies' named entity 'glycoprotein' named entity 'intracellular' named entity 'immune responses' named entity 'IgG/IgM' named entity 'mononuclear cells' named entity 'Multivariable analysis' named entity 'viral particles' named entity 'Nanjing' named entity 'IgG antibodies' named entity 'IFNγ' named entity 'headache' named entity 'adverse reactions' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software